Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors

Creative Commons License

Atalar B., Mustafayev T., Sio T., Sahin B., Gungor G., Aydın G., ...More

Radiology and Oncology, vol.54, no.4, pp.480-487, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 54 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.2478/raon-2020-0039
  • Journal Name: Radiology and Oncology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Agricultural & Environmental Science Database, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals
  • Page Numbers: pp.480-487
  • Keywords: lung cancer, radiation, stereotactic ablative radiotherapy, stereotactic body radiation therapy, survival outcomes, toxicity, BODY RADIATION-THERAPY, CELL LUNG-CANCER, EARLY-STAGE, PHASE-II
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes


Background. Stereotactic ablative radiotherapy (SABR) is effective for thoracic cancer and metastases; however, adverse effects are greater for central tumors. We evaluated factors affecting outcomes and toxicities after SABR for patients with primary lung and oligometastatic tumors.